Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous DNase I for Sepsis
NCT05453695Phase 1Recruiting
- Sponsor
- McMaster University
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of dornase alfa in sepsis, sponsored by McMaster University. Primary endpoints: Number of patients recruited per month at 24 months and Number of patients who completed the protocol at 7 days. Started Jan 2023; status: recruiting.
02
Drugs
dornase alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05453695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453695.